Could an ancient herb ease Chemo's worst side effects?

NCT ID NCT03314805

Completed Symptom relief Sponsor: PhytoHealth Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether PG2, a compound from the astragalus root, can reduce fatigue and low white blood cell counts caused by chemotherapy in women with stage II or III breast cancer. Participants receive either PG2 or a placebo alongside their standard chemotherapy. The goal is to see if PG2 helps patients tolerate treatment better and stick with their full course of chemo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PG2 (astragalus polysaccharides)
What this could lead to: If it works, PG2 could offer a natural way to ease chemotherapy side effects like fatigue and low white blood cell counts, helping patients complete their treatment.
What could go wrong: This is a small Phase 2 trial, so results may not apply broadly. PG2 may not reduce side effects better than placebo, and its safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired agranulocytosis breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Chang Gung Memorial Hospital, Kaohsiung Branch

Kaohsiung City, 833, Taiwan
Chang Gung Memorial Hospital, Linkou Branch

Taoyuan City, 333, Taiwan
Chang Gung Memorial Hospital, Lovers Lake branch

Keelung, 204, Taiwan
Chang Gung Memorial Hospital, Taipei Branch

Taipei, 105, Taiwan
E-Da Cancer Hospital

Kaohsiung City, 824, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.